192 related articles for article (PubMed ID: 18922903)
1. Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Van Schaeybroeck S; Kelly DM; Kyula J; Stokesberry S; Fennell DA; Johnston PG; Longley DB
Cancer Res; 2008 Oct; 68(20):8312-21. PubMed ID: 18922903
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
Van Schaeybroeck S; Kyula JN; Fenton A; Fenning CS; Sasazuki T; Shirasawa S; Longley DB; Johnston PG
Cancer Res; 2011 Feb; 71(3):1071-80. PubMed ID: 21148749
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
[TBL] [Abstract][Full Text] [Related]
5. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.
Kyula JN; Van Schaeybroeck S; Doherty J; Fenning CS; Longley DB; Johnston PG
Clin Cancer Res; 2010 Jul; 16(13):3378-89. PubMed ID: 20570921
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W
J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326
[TBL] [Abstract][Full Text] [Related]
8. Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids.
Nagathihalli NS; Beesetty Y; Lee W; Washington MK; Chen X; Lockhart AC; Merchant NB
Cancer Res; 2014 Apr; 74(7):2062-72. PubMed ID: 24520077
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation.
Chen L; Meng Y; Guo X; Sheng X; Tai G; Zhang F; Cheng H; Zhou Y
Apoptosis; 2016 Nov; 21(11):1291-1301. PubMed ID: 27629794
[TBL] [Abstract][Full Text] [Related]
10. TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.
Heijink DM; Jalving M; Oosterhuis D; Sloots IA; Koster R; Hollema H; Kleibeuker JH; Koornstra JJ; de Vries EG; de Jong S
J Pathol; 2011 Feb; 223(3):378-89. PubMed ID: 21171083
[TBL] [Abstract][Full Text] [Related]
11. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer.
Merchant NB; Voskresensky I; Rogers CM; Lafleur B; Dempsey PJ; Graves-Deal R; Revetta F; Foutch AC; Rothenberg ML; Washington MK; Coffey RJ
Clin Cancer Res; 2008 Feb; 14(4):1182-91. PubMed ID: 18281553
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
13. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
14. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
Kim SL; Min IS; Park YR; Lee ST; Kim SW
Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
[TBL] [Abstract][Full Text] [Related]
15. Combination of long-acting TRAIL and tumor cell-targeted photodynamic therapy as a novel strategy to overcome chemotherapeutic multidrug resistance and TRAIL resistance of colorectal cancer.
She T; Shi Q; Li Z; Feng Y; Yang H; Tao Z; Li H; Chen J; Wang S; Liang Y; Cheng J; Lu X
Theranostics; 2021; 11(9):4281-4297. PubMed ID: 33754061
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
[TBL] [Abstract][Full Text] [Related]
17. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.
Meijer A; Kruyt FA; van der Zee AG; Hollema H; Le P; ten Hoor KA; Groothuis GM; Quax WJ; de Vries EG; de Jong S
Br J Cancer; 2013 Nov; 109(10):2685-95. PubMed ID: 24136147
[TBL] [Abstract][Full Text] [Related]
18. Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.
Bosman MC; Reis CR; Schuringa JJ; Vellenga E; Quax WJ
J Biol Chem; 2014 Jan; 289(2):1071-8. PubMed ID: 24280212
[TBL] [Abstract][Full Text] [Related]
19. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
Li Q; Zhang D; Chen X; He L; Li T; Xu X; Li M
Sci Rep; 2015 Nov; 5():16082. PubMed ID: 26542452
[TBL] [Abstract][Full Text] [Related]
20. A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17.
Maretzky T; Zhou W; Huang XY; Blobel CP
Oncogene; 2011 Feb; 30(5):611-8. PubMed ID: 20871631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
